Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 11 patents granted in the last 365 days
Enanta Pharmaceuticals Inc. is addressing 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. The portfolio is distributed across 3 distinct examiners and 3 distinct art units, with no overlap between them. HEITMEIER, KENDALL NICOLE is the busiest examiner, currently handling 1 pending action.
The presence of 3 actions, 3 examiners, and 3 art units indicates a fragmented prosecution landscape. Practitioners must develop unique strategies for each application to satisfy the different technical and procedural expectations of the 3 separate art units. This distribution requires a highly individualized approach to each filing within the portfolio.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| §102 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KOSAR, ANDREW D | 1 | 41.9% | +31.9% |
| ANDERSON, REBECCA L | 1 | 73.3% | +23.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18509403 | MACROCYCLIC CHALCONE-AMIDE DERIVED ANTIVIRAL AGENTS | KOSAR, ANDREW D | — |
| 18139506 | PYRIMIDINONE-CONTAINING 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS | ANDERSON, REBECCA L | — |
| Art Unit | Apps |
|---|---|
| 1625 | 1 |
| 1626 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18509403 | MACROCYCLIC CHALCONE-AMIDE DERIVED ANTIVIRAL AGENTS | KOSAR, ANDREW D | 1625 | §102 | Non-Final OA | — | Pending | Nov 15, 2023 |
| 18139506 | PYRIMIDINONE-CONTAINING 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS | ANDERSON, REBECCA L | 1626 | §103 | Final Rejection | — | Pending | Apr 26, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialEnanta Pharmaceuticals Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Andrew D Kosar has the most, with 1 of Enanta Pharmaceuticals Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
